Waters, Quest Diagnostics Collaborate to Expand Access to At-Home HPV Screening for Cervical Cancer

09:14 AM EDT, 10/20/2026 (MT Newswires) -- Waters (WAT) and Quest Diagnostics (DGX) have entered into a collaboration aiming to widen US access to at-home HPV screening for cervical cancer, the two companies said Tuesday. Starting in 2027, the collaboration will provide access to the Onclarity Self-Collection Kit through clinical, health plan, and consumer health channels, as well as Quest's patient service centers, according to a statement. Financial terms were not disclosed.